期刊文献+

可溶性MICA抗原在湖南地区汉族恶性肿瘤患者血清中的分布及临床意义 被引量:1

The Distribution and Clinical Significance of sMICA Antigens in Malignant Tumor in Han Population in Hunan Province
下载PDF
导出
摘要 目的研究湖南地区汉族人群中可溶性MHCⅠ类链相关基因A(sMICA)分子在恶性肿瘤中的分布及诊断价值。方法双抗体夹心法检测512例恶性肿瘤患者和141例正常对照血清中sMICA浓度含量,分析sMICA含量在不同疾病中含量变化及其与疾病的相关性。结果 sMICA含量在恶性肿瘤中只有肝癌有诊断价值(AUC=0.843),而其他恶性肿瘤的诊断价值意义不大。肝癌患者血清中的sMICA含量最高,为743.4±304.1pg/mL(P=0.003),明显高于其他恶性肿瘤,胃癌次之,最差的为女性生殖系统肿瘤和恶性淋巴瘤,分别为162.5±116.1 pg/mL(P=0.115)和140.9±137.6 pg/mL(P=0.205)。结论肝癌患者血清sMICA含量明显增加,sMICA含量可应用于肝癌的诊断,而对其他恶性肿瘤的诊断价值意义不大。 Objective To study the distribution and the diagnosis value of sMICA molecules in malignant tumor in Hunan province Han population. Methods The serum level of sMICA in 512 patients with malignant tumor and 141 ca ses of normal controls was detected by doubleantibody sandwich assay method and the content changes in different diseases and correlation were analyzed. Results We found that the serum levels of sMICA exhibited diagnosis value only in live cancer (AUC = 0. 843 ). We also found that patients with liver cancer had the highest level of sMICA (743.4 ± 304.1 pg/ mL) (P = 0. 003 )in all the patients with different types of malignant cancers. In addition, patients with gastric cancer had the second highest. The patients with female reproductive system tumors and malignant lymphoma had the lowest serum lev els of sMICA ( 162.5 ± 116.1 pg/mL,P 〉 0.05 ;140.9 ±137.6 pg/mL,P 〉 0.05 ). However, only the serum levels of MI CA in the patients with liver cancer showed statistic significance. Conclusion We found that the the serum levels of sMICA were significantly increased in liver cancer, sMICA level can be applied to the diagnosis of liver cancer and cannot be applied to other malignancies.
出处 《中南医学科学杂志》 CAS 2012年第4期364-367,共4页 Medical Science Journal of Central South China
基金 湖南省教育厅项目支助(11C1110)
关键词 可溶性MHCⅠ类链相关基因A 肝癌 恶性肿瘤 sMICA live cancer malignant tumor
  • 相关文献

参考文献2

二级参考文献22

  • 1Botti C, Seregni E, Ferrari L, et al. Immunosuppressive factor: role in caneer development and progression [ J ]. Int J Biol Markers, 1998, 13(2):51.
  • 2Garrido F, Ruiz- Cabello F, Cabrera T, et al. Immunosuvelliance of altered HLA class Ⅰ phenol types in human tumours [ J ]. Immunol Today, 1997,18(2) :89.
  • 3Porgador A, Mandelbm O, Restifo N, et al. Natural killer cell lines kill antologous β2 - microglobulin deficient melanoma cells: implications for Cancer immunotherapy [ J ]. Prol Natl Acad Sci USA,1997,94(24) :13140.
  • 4McMaster MT, Librach CL. Zhou Y, et al. Human placental HLA- G expression is restricted to differential cytotrophoblasts [ J ]. Immunol, 1995,154(8) : 3771.
  • 5Chang C, Campoli M, Ferrone S. HLA class Ⅰ antigen expression in maligant cells: why does it not always correlate with CTL- mediated lysis [J]. Curropin Immunol,2004,16:644 - 650.
  • 6Bralld VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell CD94/ NkG2A, Bande[J]. Nature, 1998, 391 : 795 - 799.
  • 7Carosella ED, Moreau P, Le Maoult J, et al. HLA - G molecules from matemal- fetal tolerance to tissue acceptance [J]. Adv Immunol, 2003,81 : 199 - 252.
  • 8Lila N, Rouas - Fresis N, Daussee J, et al. Soluble HLA - G protein secreted by allospecific CD4^+ T cells suppresses the allo - proliferative response: a CD4^+ T cell regulatory mechanism [J] .Proc Natl Acad Sci USA,2001,98(12) :50 - 55.
  • 9Sophie lefebvre, Martine Antoine, Serge Uzan. Specific acfivation of the non - classical class Ⅰ histocompatibility HLA- G antigen and expression of the ILT - 2 inhibitory receptor in human breast cancer[J]. Pathology, 2002, 196: 266 - 274.
  • 10Badwe RA, Thorat MA, ParmarVV, et al. Sentinel node biopsy in breast cancer[J]. N Engl J Med,2003,349: 1968- 1971.

共引文献15

同被引文献14

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部